Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial.
Authors
Xuewei Ding
Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Xuewei Ding , Bin Li , Qiang Xue , Mingzhi Cai , Jingli Cui , Baogui Wang , Bin Ke , Rupeng Zhang , Han Liang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR2100043572
DOI
10.1200/JCO.2022.40.4_suppl.294
Abstract #
294
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC).
First Author: Xuewei Ding
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Perioperative penpulimab plus anlotinib combined with chemotherapy for locally advanced gastric cancer: A single arm, multicenter, phase II clinical trial.
First Author: Mian Wang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.
First Author: Junwei Wu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.
First Author: Miao Wang